Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult indian patients with osteoarthritis of the hip or knee: A 4-week, double-blind, randomized, comparative, multicenter study

Current Therapeutic Research - Clinical and Experimental

Volumn 70, Issue 1, 2009, Pages 56-68

  Goregaonkar, Arvind ^a   Mathiazhagan, K J ^b   Shah, Ravindra R ^c   Kapoor, Paramjeet Singh ^d   Taneja, Praveen ^e   Sharma, Akhilesh ^f   Bolmall, Chandrashekhar ^f   Baliga, Vidyagauri P ^f  

^a LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL   (India)

^b M R Hospital   (India)

^c Khwaja Banda Nawaz Institute of Medical Sciences   (India)

^d Grecian Super Speciality Hospital   (India)

^e RGS Healthcare Pvt Ltd   (India)

^f Glenmark Pharmaceuticals Limited   (India)

Author keywords

diclofenac; India; lornoxicam; osteoarthritis

Indexed keywords

DICLOFENAC; LORNOXICAM; PARACETAMOL;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; INDIAN; INTRACTABLE PAIN; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; VISUAL ANALOG SCALE; VOMITING;

EID: 62849116738     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2009.02.006     Document Type: Article

References (12)

1. Bannwarth B. Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 20 (2006) 117-129
2. Pruss T.O., Stroissing H., Radhofer-Welte S., et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J 66 Suppl 4 (1990) S18-S21
3. Berry H., Bird H.A., Black C., et al. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis 51 (1992) 238-242
4. Rose P., and Steinhauser C. Comparison of lornoxicam and rofecoxib in patients with activated osteoarthritis (COLOR Study). Clin Drug Investig 24 (2004) 227-236
5. Kidd B., and Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 23 (1996) 1605-1611
6. Altman R., Asch E., Bloch D., et al., Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 29 (1986) 1039-1049
7. Altman R., Alarcón G., Appelrouth D., et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 34 (1991) 505-514
8. Balfour J.A., Fitton A., and Barradell L.B. Lornoxicam: A review of its pharmacology and therapeutic potential in the management of painful inflammatory conditions. Drugs 51 (1996) 639-657
9. Todd P.A., and Sorken E.M. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 35 (1988) 244-285
10. Ghosh S., Paul S., Das N., and Bhattacharyya T.K. A study on the effects of diclofenac sodium and etoricoxib in the treatment of osteoarthritis. J Indian Med Assoc 105 (2007) 260-262
11. Banning M. The use of topical diclofenac for pain in osteoarthritis of the knee: A review. Br J Community Nurs 11 (2006) 487-492
12. Aabakken L., Osnes M., and Frenzel W. Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aliment Pharmacol Ther 10 (1996) 151-156